Familial Chylomicronemia (Type I Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2017

  • ID: 4396711
  • Clinical Trials
  • Region: Global
  • 44 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • ICON Plc
  • Ionis Pharmaceuticals Inc
  • Kadmon Corp LLC
  • Medpace Holdings Inc
  • Novartis AG
  • Novelion Therapeutics Inc
  • MORE
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2017

Summary

The clinical trial report, “Familial Chylomicronemia (Type I Hyperlipoproteinemia) Global Clinical Trials Review, H2, 2017" provides an overview of Familial Chylomicronemia (Type I Hyperlipoproteinemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Familial Chylomicronemia (Type I Hyperlipoproteinemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Clinical Trial Reports are generated using the author’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • ICON Plc
  • Ionis Pharmaceuticals Inc
  • Kadmon Corp LLC
  • Medpace Holdings Inc
  • Novartis AG
  • Novelion Therapeutics Inc
  • MORE
Report Guidance
Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Countries Contributing to Clinical Trials in Middle East and Africa
Top Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Familial Chylomicronemia (Type I Hyperlipoproteinemia)
Jul 11, 2017: New Data Reveal Hidden Burden of Familial Chylomicronaemia Syndrome
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About
Contact
Source

List of Tables
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Central and South America, Top Countries, 2017*
Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*

List of Figures
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Region (%), 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017*
Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
Proportion of Familial Chylomicronemia (Type I Hyperlipoproteinemia) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Phase (%), 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics, Global, Clinical Trials by Trial Status, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, by End Point Status, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
Methodology
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Ionis Pharmaceuticals Inc
  • Novartis AG
  • Medpace Holdings Inc
  • Novelion Therapeutics Inc
  • UniQure NV
  • Richmond Pharmacology Ltd
  • Kadmon Corp LLC
  • ICON Plc
  • Catabasis Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll